Renal cell carcinoma (RCC) is a common malignancy of the urinary tract. In the United States, 81,000 new cases of RCC were diagnosed in 2023, and there were 14,890 related deaths 1. RCC’s grading ...
Renal cell carcinoma (RCC), the most common kidney cancer in adults, accounts for roughly 3% of all cancers 1. For patients with non-metastatic RCC, surgical resection remains the primary and ...
Patients with lupus nephritis receiving obinutuzumab plus standard therapy demonstrated high rates of complete histologic remission.
HealthDay on MSN
FDA approves Welireg with pembrolizumab for renal cell carcinoma
The U.S. Food and Drug Administration has approved Welireg (belzutifan) in combination with pembrolizumab or pembrolizumab ...
The U.S. Food and Drug Administration (FDA) has approved pembrolizumab, an immunotherapy, plus belzutifan, a HIF-2α inhibitor, as adjuvant treatment for adult patients with renal cell carcinoma with a ...
Belzutifan, a first-in-class drug that arose from scientific discoveries at UT Southwestern Medical Center, has been approved ...
The management of renal cell carcinoma (RCC) has transformed over the past 20 years, and recent advances in diagnostic and therapeutic modalities have the potential to further improve patient outcomes ...
Renal cell carcinoma is the most common form of kidney cancer. It can take time to fully process a diagnosis and what, exactly, it may mean. Developing a good understanding of your disease—and ...
Renal cell carcinoma (RCC) is one of the 10 most commonly diagnosed solid tumors. Most RCCs are histologically defined as clear cell, comprising approximately 75% of diagnoses. However, the remaining ...
Hereditary leiomyomatosis and renal-cell cancer (HLRCC) is an inherited disorder characterized by germline pathogenic variants in the gene encoding fumarate hydratase and an increased risk of ...
Regulatory clearance includes IV pembrolizumab and subcutaneous pembrolizumab/berahyaluronidase with belzutifan for adjuvant treatment after nephrectomy, including ...
The FDA approved belzutifan with pembrolizumab as an adjuvant treatment for adults with clear cell renal cell carcinoma and a high risk for recurrence after nephrectomy, according to a press ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results